Last updated: 5 months ago
Sanofi's December 2024 Form 6-K: FDA Breakthrough for Tolebrutinib & Duvakitug Updates
Discover Sanofi's latest Form 6-K, detailing FDA designations and promising study results for Tolebrutinib and Duvakitug, crucial for investors and stakeholders.